Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease: Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry

B. Glintborg; T. M. Kringelbach; E. Høgdall; I. J. Sørensen; D. V. Jensen; A. G. Loft; O. Hendricks; I. M. Jensen Hansen; N. Bolstad; K. Grøn; G. Eng; C. Enevold; C. H. Nielsen; D. Warren; G. Goll; J. Gehin; J. S. Johansen; M. L. Hetland

doi:10.1136/annrheumdis-2016-eular.1477

Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease: Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry

B. Glintborg, T. M. Kringelbach, E. Høgdall, I. J. Sørensen, D. V. Jensen, A. G. Loft, O. Hendricks, I. M. Jensen Hansen, N. Bolstad, K. Grøn, G. Eng, C. Enevold, C. H. Nielsen, D. Warren, G. Goll, J. Gehin, J. S. Johansen, M. L. Hetland

Institut for Klinisk Medicin

Originalsprog	Engelsk
Artikelnummer	THU0123
Tidsskrift	Annals of the Rheumatic Diseases
Vol/bind	75
Udgave nummer	Suppl 2
Antal sider	1
ISSN	0003-4967
DOI	https://doi.org/10.1136/annrheumdis-2016-eular.1477
Status	Udgivet - 2016

Adgang til dokumentet

10.1136/annrheumdis-2016-eular.1477

Citationsformater

Glintborg, B., Kringelbach, T. M., Høgdall, E., Sørensen, I. J., Jensen, D. V., Loft, A. G., Hendricks, O., Jensen Hansen, I. M., Bolstad, N., Grøn, K., Eng, G., Enevold, C., Nielsen, C. H., Warren, D., Goll, G., Gehin, J., Johansen, J. S., & Hetland, M. L. (2016). Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease: Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry. Annals of the Rheumatic Diseases, 75(Suppl 2), Artikel THU0123 . https://doi.org/10.1136/annrheumdis-2016-eular.1477

Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease: Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry. / Glintborg, B.; Kringelbach, T. M.; Høgdall, E. et al.
I: Annals of the Rheumatic Diseases, Bind 75, Nr. Suppl 2, THU0123 , 2016.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Glintborg, B, Kringelbach, TM, Høgdall, E, Sørensen, IJ, Jensen, DV, Loft, AG, Hendricks, O, Jensen Hansen, IM, Bolstad, N, Grøn, K, Eng, G, Enevold, C, Nielsen, CH, Warren, D, Goll, G, Gehin, J, Johansen, JS & Hetland, ML 2016, 'Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease: Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry', Annals of the Rheumatic Diseases, bind 75, nr. Suppl 2, THU0123 . https://doi.org/10.1136/annrheumdis-2016-eular.1477

Glintborg B, Kringelbach TM, Høgdall E, Sørensen IJ, Jensen DV, Loft AG et al. Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease: Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry. Annals of the Rheumatic Diseases. 2016;75(Suppl 2):THU0123 . doi: 10.1136/annrheumdis-2016-eular.1477

@article{edff73d67eba41bca8a80ad7c32cdfb0,

title = "Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease: Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry",

author = "B. Glintborg and Kringelbach, {T. M.} and E. H{\o}gdall and S{\o}rensen, {I. J.} and Jensen, {D. V.} and Loft, {A. G.} and O. Hendricks and {Jensen Hansen}, {I. M.} and N. Bolstad and K. Gr{\o}n and G. Eng and C. Enevold and Nielsen, {C. H.} and D. Warren and G. Goll and J. Gehin and Johansen, {J. S.} and Hetland, {M. L.}",

year = "2016",

doi = "10.1136/annrheumdis-2016-eular.1477",

language = "English",

volume = "75",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "B M J Group",

number = "Suppl 2",

}

TY - ABST

T1 - Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease

T2 - Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry

AU - Glintborg, B.

AU - Kringelbach, T. M.

AU - Høgdall, E.

AU - Sørensen, I. J.

AU - Jensen, D. V.

AU - Loft, A. G.

AU - Hendricks, O.

AU - Jensen Hansen, I. M.

AU - Bolstad, N.

AU - Grøn, K.

AU - Eng, G.

AU - Enevold, C.

AU - Nielsen, C. H.

AU - Warren, D.

AU - Goll, G.

AU - Gehin, J.

AU - Johansen, J. S.

AU - Hetland, M. L.

PY - 2016

Y1 - 2016

U2 - 10.1136/annrheumdis-2016-eular.1477

DO - 10.1136/annrheumdis-2016-eular.1477

M3 - Conference abstract in journal

SN - 0003-4967

VL - 75

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - Suppl 2

M1 - THU0123

ER -